Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review
PLOS ONE · 30.11.2023 · 18 (11) · e0285335
DOI: 10.1371/journal.pone.0285335 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 30.11.2023. Verfasst von Zhehao Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of medical oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Acromegaly, Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, The Traditional Chinese Medicine Administration Project of Jiangxi Province.
Abstract (Originalsprache)
The incidence of cancer in acromegaly patients may be higher than that in the general population, although this has not been fully elucidated yet. This study analyzed the risk of various important types of cancer in acromegaly patients. The study was registered in INPLASY (registration number: INPLASY202340037). The PubMed, Web of Science, and EMBASE databases were searched for studies based on strict inclusion and exclusion criteria, from the time of database inception up to June 30, 2022. All observational studies of acromegaly patients with cancer were included, without language restrictions. We used the Newcastle–Ottawa scale (NOS) checklist to assess the quality of evidence. A meta-analysis revealed the relationship between acromegaly and cancer using the standardized incidence rates (SIRs) and 95% confidence intervals (CIs) retrieved from the included studies. Nineteen studies were included and analyzed. The overall incidence of cancer (SIR = 1.45, 95%CI = 1.20–1.75), as well as that of thyroid (SIR = 6.96, 95%CI = 2.51–19.33), colorectal and anal (SIR = 1.95, 95%CI = 1.32–2.87), brain and central nervous system (SIR = 6.14, 95%CI = 2.73–13.84), gastric (SIR = 3.09, 95%CI = 1.47–6.50), urinary (SIR = 2.66, 95%CI = 1.88–3.76), hematological (SIR = 1.89, 95%CI = 1.17–3.06), pancreatic and small intestine (SIR = 2.59, 95%CI = 1.58–4.24), and connective tissue (SIR = 3.15, 95%CI = 1.18–8.36) cancers, was higher among patients with acromegaly than among the general population. No association between acromegaly and hepatobiliary, respiratory, reproductive, skin, breast, or prostate cancer was observed. This study demonstrated that acromegaly patients have a modestly increased chance of cancer as compared to the general population. Risk factors for cancer need to be further explored to monitor patients with acromegaly at a high risk for cancer more carefully.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of medical oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- College of Physics Science and Engineering Technology, Yichun University, Yichun, China.
ORCID-Profile: Yong Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- The Traditional Chinese Medicine Administration Project of Jiangxi Province
Zitieren
APA
Xiao, Z., Xiao, P., Wang, Y., Fang, C., & Li, Y. (2023). Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review. PLOS ONE, 18(11), e0285335. https://doi.org/10.1371/journal.pone.0285335
Vancouver
Xiao Z, Xiao P, Wang Y, Fang C, Li Y. Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review. PLOS ONE. 2023;18(11):e0285335. doi:10.1371/journal.pone.0285335
BibTeX
@article{Xiao2023,
author = {Xiao, Zhehao and Xiao, Pingping and Wang, Yong and Fang, Chen and Li, Yong},
title = {Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {11},
pages = {e0285335},
doi = {10.1371/journal.pone.0285335}
}
EUVIMED